MedTrace Logo

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

NCT01152606 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3942

Last updated 2018-01-25

No results posted yet for this study

Summary

This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.

Conditions

Interventions

DRUG

trastuzumab [Herceptin]

There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Austria
  • Belgium
  • Germany
  • Hungary
  • Italy
  • Poland
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152606 on ClinicalTrials.gov